THE ABSORPTION AND DISTRIBUTION OF AUREOMYCIN IN MAN: A REVIEW OF THE LITERATURE AND STUDY OF THE CONCENTRATION OF AUREOMYCIN IN THE SERUM, URINE AND CEREBROSPINAL FLUID AFTER ORAL ADMINISTRATION
Authors: B HALL
Journal: Annals of Internal Medicine (1954)

Article1 April 1954THE ABSORPTION AND DISTRIBUTION OF AUREOMYCIN IN MAN: A REVIEW OF THE LITERATURE AND STUDY OF THE CONCENTRATION OF AUREOMYCIN IN THE SERUM, URINE AND CEREBROSPINAL FLUID AFTER ORAL ADMINISTRATIONBUFORD HALL, M.D.BUFORD HALL, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-40-4-743 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptAureomycin has now been in clinical use for more than five years. The voluminous and still growing literature concerned with this antibiotic relates chiefly to its clinical trial in various diseases, there being relatively few studies of its distribution in various body fluids. This situation may be partly explained by technical difficulties resulting from instability of Aureomycin solutions at room temperature, particularly at a neutral pH.1In this paper we propose to summarize the knowledge concerning the absorption, diffusion and excretion of Aureomycin after oral administration, based on data in the literature and on more than 400 previously unreported determinations...Bibliography1. DornbushPelcak ACEJ: The determination of Aureomycin in serum and other body fluids, Ann. New York Acad. Sc. 51: 218-220, 1948. CrossrefMedlineGoogle Scholar2. RandallTaylorWellman RVRWWE: Intravenous administration of Aureomycin including studies on the concentration in the serum, Proc. Staff Meet., Mayo Clin. 24: 605-611, 1949. MedlineGoogle Scholar3. DowlingLepperCaldwellWheltonBrickhouse HFMHERRLRL: The concentration of Aureomycin in urine and cerebrospinal, pleural and ascitic fluids after oral and intravenous administration, J. Clin. Investigation 28: 983-986, 1949. CrossrefGoogle Scholar4. SandersRumballSolomonSoretRicci MJMCMGNI: Further experiences with intravenous Aureomycin therapy: a study of 116 cases, J. Clin. Investigation 28: 1006-1013, 1949. CrossrefGoogle Scholar5. WhitlockHuntTashman CMADSG: Studies on the administration, absorption, distribution and excretion of Aureomycin in children, Pediatrics 6: 827-842, 1950. MedlineGoogle Scholar6. GockeWellsCollinsFinland TMEBHSM: Blood levels and urinary excretion of Aureomycin after intravenous and intramuscular administration, J. Lab. and Clin. Med. 36: 100-112, 1950. MedlineGoogle Scholar7. BrainerdBruynMeiklejohnScaparone HDHBGM: Assay of Aureomycin in body fluids. Observations on individuals receiving Aureomycin, Proc. Soc. Exper. Biol. and Med. 70: 318-321, 1949. CrossrefMedlineGoogle Scholar8. DowlingLepperCaldwellWheltonSweet HFMHERRLLK: Aureomycin in various infections: report of one-hundred eighty cases and review of the clinical literature, M. Ann. District of Columbia 18: 335-345, 1949. MedlineGoogle Scholar9. LepperDowlingBrickhouseCaldwell MHHFRLER: Blood and cerebrospinal fluid concentrations of Aureomycin after oral and intramuscular administration, J. Lab. and Clin.. Med. 34: 366-371, 1949. MedlineGoogle Scholar10. WernerKnightMcDermott CAWW: Absorption and excretion of Terramycin in humans: comparison with Aureomycin and chloramphenicol, Proc. Soc. Exper. Biol. and Med. 74: 261-267, 1950. CrossrefMedlineGoogle Scholar11. RodriquezPlotkeWeinsteinHarris JFSWW: Aureomycin and its effect in early syphilis. Progress report, Arch. Dermat. and Syph. 63: 433-439, 1951. CrossrefGoogle Scholar12. GreenspanMacLeanMilzerNecheles RHAH: Antacids and Aureomycin, Am. J. Digest. Dis. 18: 35-37, 1951. CrossrefMedlineGoogle Scholar12. Welch H(a) : Absorption, excretion and distribution of Terramycin, Ann. New York Acad. Sc. 53: 253-265, 1950. CrossrefMedlineGoogle Scholar13. MichelSayerKirby JCRJWM: Effect of food and antacids on blood levels of Aureomycin and Terramycin, J. Lab. and Clin. Med. 36: 632-634, 1950. MedlineGoogle Scholar14. HerrellHeilman WEFR: Aureomycin. Studies on absorption, diffusion and excretion, Proc. Staff Meet., Mayo Clin. 24: 157-166, 1949. MedlineGoogle Scholar15. SeedWilson JCCE: The effect of aluminum hydroxide on serum Aureomycin concentrations after simultaneous oral administration, Bull. Johns Hopkins Hosp. 86: 415-418, 1950. MedlineGoogle Scholar16. WilliamsWeekes MLDJ: The effect of antacid preparations on serum Aureomycin levels, Rev. Gastroenterol. 18: 128-130, 1951. MedlineGoogle Scholar17. BartholomewNichols LHDR: Use of milk to control vomiting caused by Aureomycin, Proc. Staff Meet., Mayo Clin. 25: 370-373, 1950. MedlineGoogle Scholar18. ManningWellman PRWE: Aureomycin calcium caseinate: a new preparation associated with a low incidence of nausea and vomiting, Proc. Staff Meet., Mayo Clin. 27: 89-93, 1952. MedlineGoogle Scholar19. DowlingLepperSweetBrickhouse HFMHLKRL: Studies on serum concentrations in humans and preliminary observations on the treatment of human infections with Aureomycin, Ann. New York Acad. Sc. 51: 241-245 (Nov. 30) 1948. CrossrefMedlineGoogle Scholar20. SchneiersonToharsky SSB: A method for the determination of Aureomycin in the blood, J. Bact. 57: 483-487, 1949. CrossrefMedlineGoogle Scholar21. WolfeLepperCaldwellSpiesDowling CKMHERHWHF: Treatment of nontuberculous bacterial pleural space infections with Aureomycin: results of treatment in nine patients: concentrations of Aureomycin in pleural and pericardial fluid in seven patients, Ann. Int. Med. 37: 164-171, 1952. LinkGoogle Scholar22. WaisbrenHueckel BAJS: Reduced absorption of Aureomycin caused by aluminum hydroxide gel (Amphojel), Proc. Soc. Exper. Biol. and Med. 73: 73-74, 1950. CrossrefMedlineGoogle Scholar23. BogerMatteucciBeattyBaganz WPWVJOHM: Aureomycin plasma concentrations influenced by aluminum hydroxide, J. Philadelphia Gen. Hosp. 1: 3-7, 1950. Google Scholar23. Eisner HJ(a) Performed by ; Personal Communication from S. M. Hardy, M.D. Google Scholar24. BryerSchoenbachChandlerBlissLong MSEBCAEAPH: Aureomycin—Experimental and clinical investigations, J. A. M. A. 138: 117-119, 1948. CrossrefMedlineGoogle Scholar25. CollinsWellsPaineFinland HSEBTFM: Urinary excretion of Aureomycin, Proc. Soc. Exper. Biol. and Med. 69: 174-175, 1948. CrossrefMedlineGoogle Scholar26. ChandlerHodes CAHL: Aureomycin in the treatment of experimental and clinical infections with H. influenzae, type B, Pediatrics 5: 267-275, 1950. MedlineGoogle Scholar27. GuilbeauSchoenbachSchaubLatham JAEBIGDV: Aureomycin in obstetrics: therapy and prophylaxis, J. A. M. A. 143: 520-526, 1950. CrossrefMedlineGoogle Scholar28. ZaslowHewlettGoldsmith JTHR: The excretion and concentration of Aureomycin in the abnormal human biliary tract: II. Hepatic bile, Gastroenterology 16: 479-483, 1950. CrossrefMedlineGoogle Scholar29. ZaslowHewlettLorry JTHRW: The excretion and concentration of Aureomycin in the abnormal human biliary tract: I. Gallbladder, Gastroenterology 16: 475-478, 1950. CrossrefMedlineGoogle Scholar30. Cole LR: Recovery of Aureomycin from the gastrointestinal tract following intravenous administration, J. Lab. and Clin. Med. 41: 670-675, 1953. MedlineGoogle Scholar31. KrausCaseyJohnson FWDWV: Aureomycin and Terramycin in human saliva, Proc. Soc. Exper. Biol. and Med. 78: 554-558, 1951. CrossrefMedlineGoogle Scholar32. KirsnerLevinPalmer JBEWL: Use of antibiotics in gastrointestinal diseases: a review, Arch. Int. Med. 90: 677-706, 1952. CrossrefGoogle Scholar33. DornbushMetzgerShapse ACWIJB: Evaluation of oral Aureomycin for intestinal antisepsis, J. Bact. 59: 309-310, 1950. CrossrefMedlineGoogle Scholar34. Robbins WC: Depression of fecal urobilinogen by Aureomycin and by Terramycin, Proc. Soc. Exper. Biol. and Med. 77: 158-162, 1951. CrossrefMedlineGoogle Scholar35. SborovJayWatson VMARCJ: The effect of Aureomycin on urobilinogen formation and the fecal flora, J. Lab. and Clin. Med. 37: 52-59, 1951. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Lexington, Kentucky*Received for publication September 30, 1953.From the Department of Medicine, University of Illinois College of Medicine, and the Illinois Research and Educational Hospitals, Chicago, Illinois.†Supplied by Lederle Laboratories Division, American Cyanamid Company. Aureomycin is their trade-mark for Chlortetracycline. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byOral antibiotic therapy for the treatment of infective endocarditis: a systematic reviewPhysiologische Chemie der Lebensvorgänge und OrganeTreatment of Meningitis Due to Friedländers BacillusOn the Distribution of Chlortetracycline in the Body 1 April 1954Volume 40, Issue 4Page: 743-754KeywordsAttentionBody fluidsCerebrospinal fluidClinical trialsExcretionHospital medicineOral administrationOral medicineTemperatureUrine ePublished: 1 December 2008 Issue Published: 1 April 1954 PDF downloadLoading ...